Envestnet Portfolio Solutions Inc. Has $734,000 Stake in Sotera Health Company $SHC

Envestnet Portfolio Solutions Inc. lifted its position in Sotera Health Company (NASDAQ:SHC) by 312.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 65,975 shares of the company’s stock after buying an additional 49,992 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Sotera Health were worth $734,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in SHC. UMB Bank n.a. grew its stake in shares of Sotera Health by 112.8% in the 2nd quarter. UMB Bank n.a. now owns 2,635 shares of the company’s stock valued at $29,000 after buying an additional 1,397 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of Sotera Health by 3,690.1% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,691 shares of the company’s stock valued at $31,000 after buying an additional 2,620 shares in the last quarter. Parallel Advisors LLC grew its stake in shares of Sotera Health by 124.0% in the 2nd quarter. Parallel Advisors LLC now owns 3,340 shares of the company’s stock valued at $37,000 after buying an additional 1,849 shares in the last quarter. Summit Securities Group LLC bought a new stake in shares of Sotera Health in the 1st quarter valued at approximately $67,000. Finally, Farther Finance Advisors LLC grew its stake in shares of Sotera Health by 4,881.9% in the 1st quarter. Farther Finance Advisors LLC now owns 6,327 shares of the company’s stock valued at $70,000 after buying an additional 6,200 shares in the last quarter. Institutional investors own 91.03% of the company’s stock.

Insider Activity

In other news, Director Pincus & Co. Warburg sold 12,000,000 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $15.11, for a total value of $181,320,000.00. Following the completion of the sale, the director directly owned 61,822,952 shares of the company’s stock, valued at approximately $934,144,804.72. This represents a 16.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gtcr Investment Xi Llc sold 8,000,000 shares of the stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $15.11, for a total value of $120,880,000.00. Following the completion of the sale, the director directly owned 41,215,301 shares of the company’s stock, valued at $622,763,198.11. This represents a 16.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,126,611 shares of company stock valued at $304,273,888. 55.12% of the stock is owned by company insiders.

Sotera Health Stock Up 3.4%

Shares of Sotera Health stock opened at $16.71 on Tuesday. The stock has a market capitalization of $4.75 billion, a P/E ratio of 208.90 and a beta of 1.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 4.49. The stock has a 50 day moving average price of $15.99 and a two-hundred day moving average price of $13.21. Sotera Health Company has a 12-month low of $9.53 and a 12-month high of $17.04.

Sotera Health (NASDAQ:SHC) last announced its earnings results on Friday, August 8th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.17 by $0.03. The firm had revenue of $294.34 million during the quarter, compared to analysts’ expectations of $275.81 million. Sotera Health had a return on equity of 39.42% and a net margin of 2.14%.The company’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.19 earnings per share. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. Equities analysts expect that Sotera Health Company will post 0.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Wall Street Zen raised Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Barclays boosted their price target on Sotera Health from $17.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sotera Health in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Sotera Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.20.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.